Hans‐Gustaf Ljunggren, Kenneth R Chien, EMBO reports (2015) 16, 1246-1249 DOI 10.15252/embr.201541065
Partnerships between academics, big pharma, biotech firms, philanthropists and patients look set to change the way science advances.
Interestingly, the focus of many of these partners is not so much to “translate” existing knowledge per se into medical progress, but more to foster “transcriptional medicine” by directly funding primary research and development at the early stages and by providing substantial resources to translate their own discoveries into cures for affected patient populations.
Thursday, October 15, 2015
Subscribe to:
Posts (Atom)
